These observations suggest that the blood serum concentration of IL-6 could be considered to be a diagnostic and prognostic biomarker in colorectal cancer patients that correlates with relapse-free survival and recurrence [44,45,47,53,54]. This evidence concerns the gene IL6 and colorectal cancer.